Composition and method for treating senile macular degeneration

Abstract

The invention provides a composition and method for treating senile macular degeneration, and the method comprises the following steps: preparing a pharmaceutical composition: crushing 13g of astragalus membranaceus, 15g of spina date seed, 10g of bighead atractylodes rhizome, 10g of poria cocos, 8g of longan aril, 8g of angelica sinensis, 8g of semen cuscutae, 8g of semen plantaginis, 5g of rhizoma zingiberis, 5g of ginseng, 3g of storax, 3g of ligusticum wallichii, 2g of elecampane and 2g of honey-fried licorice root, soaking in a 95% ethanol solution, refluxing for three times, each refluxing time being 15h, and filtering to obtain the pharmaceutical composition; the oral preparation is obtained by combining three times of reflux liquid medicine, concentrating and drying, the oral preparation is obtained once a day and is matched with acupuncture therapy and preparation of a pharmaceutical composition, eye microcirculation is improved by adjusting blood circulation, replenishing qi to invigorate the spleen, nourishing the liver and kidney and reinforcing qi to nourish blood, meanwhile, the level of inflammatory factors in serum of an old macular degeneration patient is reduced, and the treatment effect of the oral preparation is improved. And acupuncture and moxibustion are used for promoting regulation and stimulating the self-regulation function and the self-rehabilitation capability of the human body to achieve the treatment effect.

Description

Technical Field

[0001] The present invention belongs to the technical field of compositions and methods for treating age-related macular degeneration, and particularly relates to a composition and method for treating age-related macular degeneration. Background Art

[0002] Retinal AMD is a disease with an increasing incidence rate as people age. Clinically, it is mainly manifested as distorted vision, central scotoma, decreased central visual acuity, etc. It mostly occurs in the elderly over 50 years old, with both eyes developing the disease successively or simultaneously, and the visual acuity showing a progressive decline.

[0003] AMD is an age-related eye disease caused by the senile changes of retinal pigment epithelial cells and the retina. This disease is the primary cause of irreversible decline or even loss of central visual acuity in middle-aged and elderly people.

[0004] Currently, AMD is clinically divided into "dry" and "wet", namely atrophic and exudative. The difference lies in whether there are symptoms of bleeding, exudation, and edema in the fundus. If so, it is wet AMD, otherwise it is dry AMD. Dry AMD has a slower onset, with the visual acuity of both eyes gradually decreasing, accompanied by distorted vision, mainly manifested as patchy pigmentation or depigmentation of drusen in the macula, and degenerative changes of choroidal blood vessels in the fovea centralis of the macula. Wet AMD has a rapid onset, with the visual acuity of the affected eye suddenly decreasing, accompanied by distorted vision or central scotoma, and the fundus condition shows the formation of choroidal neovascularization under the fovea centralis of the macula. Due to the rupture of blood vessels, RPE shows bleeding, exudation, edema, and scar formation. However, due to the rapid onset of wet AMD, it causes irreversible severe decline or even loss of the patient's visual acuity in a short time. Although wet AMD only accounts for 20% of all AMD cases, the blindness rate can be as high as 80%, which has an adverse impact on the quality of life of patients and their families. Currently, there is no method for completely curing and preventing recurrence of AMD in clinical practice. Therefore, the treatment of wet AMD in clinical practice is particularly important.

[0005] Currently, most traditional Chinese ophthalmologists believe that the occurrence of AMD is mainly related to the dysfunction of the kidneys, spleen, and liver. The kidneys are the foundation of congenital constitution, and sufficient essence makes the eyes clear, so the degenerative changes of the macula are most closely related to the decline of the kidneys. The spleen and stomach are the foundation of acquired constitution and the source of qi and blood production, so the macular degeneration is most closely related to the dysfunction of the spleen's transportation and transformation function. The liver is the sea of blood, and essence and blood are mutually generated. The choroid around the macula is rich and full, so the prosperity and decline of liver blood also affect the function of the macula.

[0006] The disease syndrome of "dim and hazy vision" refers to the condition where the appearance of the eyeball is normal, there is no opacity or abnormal color in the pupil, but the patient only feels that the vision is dim and hazy. Its etiology and pathogenesis are caused by the aging of the body, the limitation of the liver and kidneys, the weakness of the spleen qi, or the accumulation of phlegm-dampness. Therefore, a composition and method for treating age-related macular degeneration are proposed. Summary of the Invention

[0007] The present invention provides a composition and a method for treating age-related macular degeneration, which solve the problems in the prior art.

[0008] A composition for treating age-related macular degeneration, characterized in that it includes the preparation of a pharmaceutical composition:

[0009] Weighing of the pharmaceutical composition: 13 - 15 g of Astragalus membranaceus, 12 - 15 g of Ziziphus jujuba var. spinosa, 8 - 10 g of Atractylodes macrocephala, 8 - 10 g of Poria cocos, 8 - 10 g of Longan aril, 8 - 10 g of Angelica sinensis, 8 - 10 g of Cuscuta chinensis, 8 - 10 g of Plantago asiatica, 5 - 8 g of Dry Ginger, 4 - 6 g of Ginseng, 3 - 6 g of Styrax, 3 - 5 g of Ligusticum chuanxiong, 2 - 4 g of Aucklandia lappa, 2 - 3 g of Honey-fried Licorice Root.

[0010] As a preferred embodiment, the pharmaceutical composition is weighed according to the weight ratio: 13 g of Astragalus membranaceus, 15 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 g of Longan aril, 8 g of Angelica sinensis, 8 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Dry Ginger, 5 g of Ginseng, 3 g of Styrax, 3 g of Ligusticum chuanxiong, 2 g of Aucklandia lappa, 2 g of Honey-fried Licorice Root.

[0011] A preparation method of a pharmaceutical composition, the specific steps are as follows:

[0012] S1: Mix 13 g of Astragalus membranaceus, 15 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 g of Longan aril, 8 g of Angelica sinensis, 8 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Dry Ginger, 5 g of Ginseng, 3 g of Styrax, 3 g of Ligusticum chuanxiong, 2 g of Aucklandia lappa, 2 g of Honey-fried Licorice Root in a crushing cavity and crush them;

[0013] S2: Soak and reflux the crushed pharmaceutical composition to prepare an oral preparation.

[0014] As a preferred embodiment, the 13 g of Astragalus membranaceus, 15 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 g of Longan aril, 8 g of Angelica sinensis, 8 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Dry Ginger, 5 g of Ginseng, 3 g of Styrax, 3 g of Ligusticum chuanxiong, 2 g of Aucklandia lappa, 2 g of Honey-fried Licorice Root are soaked in a 95% ethanol solution and refluxed three times, with each reflux time being 15 h. The three refluxed medicinal liquids are combined, concentrated and dried to obtain an oral preparation.

[0015] As a preferred embodiment, the oral preparation is taken once a day and is combined with acupuncture treatment. For the acupuncture treatment, the main and secondary acupoints are alternately acupuncture. The main acupoints are the infraorbital foramen and Sibai acupoint, and the secondary acupoints are Fengchi and Sanyinjiao.

[0016] As a preferred embodiment, the alternate acupuncture adopts a strong method of gentle twirling and lifting and thrusting.

[0017] After adopting the above technical solution, the beneficial effects of the present invention are:

[0018] 1. The pharmaceutical composition improves the microcirculation of the eyes by regulating blood circulation, tonifying qi and strengthening the spleen, nourishing the liver and kidney, and supplementing qi and nourishing blood, reducing hypoxia and inflammation in the macular area. The active ingredients such as ginseng and chuanxiong have the effects of anti-platelet aggregation, anti-thrombosis formation and vasodilation, significantly reducing the levels of inflammatory factors in the serum of patients with age-related macular degeneration.

[0019] 2. When promoting the energy metabolism of retinal cells, it means enhancing the viability of cells, which is beneficial for combating macular degeneration, reducing the damage of the optic nerve and delaying the optic nerve degeneration.

[0020] 3. Acupuncture at the infraorbital foramen and Sibai acupoints has the effects of expelling wind and improving eyesight, dredging the tendons and activating collaterals, and has a good therapeutic effect on pathological conditions such as nebula and optic nerve atrophy. Acupuncture at Fengchi and Sanyinjiao acupoints, where Sanyinjiao is the confluence point of three yin meridians, can regulate and tonify the liver, spleen and kidney. Therefore, alternate acupuncture of the main and secondary acupoints is used to promote the regulation and stimulate the body's self-regulatory function and self-healing ability to achieve the therapeutic effect.

[0021] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the embodiments. Obviously, the following descriptions are only some embodiments of the present invention. Detailed Embodiments

[0022] The following embodiments are only a part of the embodiments of the present invention, rather than all of them. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the scope of protection of the present invention.

[0023] Example 1

[0024] A composition for treating age-related macular degeneration, characterized by including the preparation of the pharmaceutical composition:

[0025] Weighing of the pharmaceutical composition: 13 - 15 g of astragalus membranaceus, 12 - 15 g of wild jujube seed, 8 - 10 g of atractylodes macrocephala, 8 - 10 g of poria cocos, 8 - 10 g of longan aril, 8 - 10 g of angelica sinensis, 8 - 10 g of cuscuta chinensis, 8 - 10 g of plantago asiatica, 5 - 8 g of dried ginger, 4 - 6 g of ginseng, 3 - 6 g of styrax, 3 - 5 g of chuanxiong, 2 - 4 g of costus root, 2 - 3 g of roasted licorice root.

[0026] Specifically, the pharmaceutical composition is weighed according to the weight ratio: 13 g of astragalus membranaceus, 15 g of wild jujube seed, 10 g of atractylodes macrocephala, 10 g of poria cocos, 8 g of longan aril, 8 g of angelica sinensis, 8 g of cuscuta chinensis, 8 g of plantago asiatica, 5 g of dried ginger, 5 g of ginseng, 3 g of styrax, 3 g of chuanxiong, 2 g of costus root, 2 g of roasted licorice root.

[0027] A preparation method of the pharmaceutical composition, the specific steps are as follows:

[0028] S1: Mix 13 g of Astragalus membranaceus, 15 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 g of Arillus longan, 8 g of Angelica sinensis, 8 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Drynaria fortunei, 5 g of Panax ginseng, 3 g of Styrax, 3 g of Ligusticum wallichii, 2 g of Aucklandia lappa, and 2 g of Radix Glycyrrhizae Preparata in a crushing chamber and crush them;

[0029] S2: Soak and reflux the crushed pharmaceutical composition to prepare an oral preparation.

[0030] Specifically, soak 13 g of Astragalus membranaceus, 15 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 g of Arillus longan, 8 g of Angelica sinensis, 8 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Drynaria fortunei, 5 g of Panax ginseng, 3 g of Styrax, 3 g of Ligusticum wallichii, 2 g of Aucklandia lappa, and 2 g of Radix Glycyrrhizae Preparata in a 95% ethanol solution, reflux three times, with each reflux time being 15 h. Combine the three refluxed medicinal liquids, and obtain the oral preparation after concentration and drying.

[0031] Specifically, take the oral preparation once a day and combine it with acupuncture treatment. For the acupuncture treatment, alternate between the main and secondary acupoints. The main acupoints are the infraorbital foramen and Sibai (ST2), and the secondary acupoints are Fengchi (GB20) and Sanyinjiao (SP6).

[0032] Specifically, the alternate acupuncture uses the strong method of gently twirling, lifting, and thrusting.

[0033] Example 2

[0034] A composition for treating age-related macular degeneration, characterized in that it includes the preparation of a pharmaceutical composition:

[0035] Weigh the pharmaceutical composition: 13 - 15 g of Astragalus membranaceus, 12 - 15 g of Ziziphus jujuba var. spinosa, 8 - 10 g of Atractylodes macrocephala, 8 - 10 g of Poria cocos, 8 - 10 g of Arillus longan, 8 - 10 g of Angelica sinensis, 8 - 10 g of Cuscuta chinensis, 8 - 10 g of Plantago asiatica, 5 - 8 g of Drynaria fortunei, 4 - 6 g of Panax ginseng, 3 - 6 g of Styrax, 3 - 5 g of Ligusticum wallichii, 2 - 4 g of Aucklandia lappa, and 2 - 3 g of Radix Glycyrrhizae Preparata.

[0036] Specifically, weigh the pharmaceutical composition according to the weight ratio: 13 g of Astragalus membranaceus, 13 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 of Arillus longan, 8 g of Angelica sinensis, 10 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Drynaria fortunei, 5 g of Panax ginseng, 3 g of Styrax, 3 g of Ligusticum wallichii, 2 g of Aucklandia lappa, and 2 g of Radix Glycyrrhizae Preparata.

[0037] A preparation method of a pharmaceutical composition, the specific steps are as follows:

[0038] S1: Mix 13 g of Astragalus membranaceus, 13 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 of Arillus longan, 8 g of Angelica sinensis, 10 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Drynaria fortunei, 5 g of Panax ginseng, 3 g of Styrax, 3 g of Ligusticum wallichii, 2 g of Aucklandia lappa, and 2 g of Radix Glycyrrhizae Preparata in a crushing chamber and crush them;

[0039] S2: Soak the broken pharmaceutical composition and reflux it to prepare an oral preparation.

[0040] Specifically, soak 13 g of Astragalus membranaceus, 13 g of Ziziphus jujuba var. spinosa, 10 g of Atractylodes macrocephala, 10 g of Poria cocos, 8 g of Longan aril, 8 g of Angelica sinensis, 10 g of Cuscuta chinensis, 8 g of Plantago asiatica, 5 g of Dry ginger, 5 g of Ginseng, 3 g of Styrax, 3 g of Ligusticum wallichii, 2 g of Aucklandia lappa, and 2 g of roasted Licorice root in a 95% ethanol solution and reflux three times, with each reflux time being 15 h. Combine the medicinal liquids from the three refluxes, and obtain the oral preparation after concentration and drying.

[0041] Specifically, take the oral preparation once a day and combine it with acupuncture treatment. For the acupuncture treatment, alternate between the main and secondary acupoints. The main acupoints are the infraorbital foramen and Sibai (ST 2), and the secondary acupoints are Fengchi (GB 20) and Sanyinjiao (SP 6).

[0042] Specifically, the alternate acupuncture uses a strong method of gently twirling, lifting, and thrusting.

[0043] The present invention provides a composition and method for treating age-related macular degeneration. Based on existing pharmacological experiments and clinical practices, extract the active ingredients from the pharmaceutical composition to prepare an oral preparation for treating age-related macular degeneration with stable quality, definite curative effect, and convenient use. Combine it with acupuncture treatment to regulate blood circulation, replenish qi and strengthen the spleen, nourish the liver and kidney, and replenish qi and nourish blood, significantly reduce the levels of inflammatory factors in the serum of patients with age-related macular degeneration, and at the same time stimulate the body's self-regulatory function and self-healing ability to achieve the therapeutic effect.

[0044] The present invention provides a composition and method for treating age-related macular degeneration. This pharmaceutical composition has opened up a new application field for pharmaceutical compositions. The above are only the preferred embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the method of the present invention, several improvements and supplements can be made, and these improvements and supplements should also be regarded as the protection scope of the present invention.

Claims

1. A composition for treating age-related macular degeneration, characterized in that: The preparation of the pharmaceutical composition comprises: The pharmaceutical composition is weighed: 13-15g of Astragalus, 12-15g of Ziziphus jujuba seeds, 8-10g of Atractylodes macrocephala, 8-10g of Poria, 8-10g of Longan pulp, 8-10g of Angelica sinensis, 8-10g of Cuscuta australis, 8-10g of Plantago seed, 5-8g of dried ginger, 4-6g of ginseng, 3-6g of Styrax, 3-5g of Ligusticum chuanxiong, 2-4g of Costus root, and 2-3g of Radix Glycyrrhizae uralensis.

2. A composition for treating age-related macular degeneration according to claim 1, characterized in that: The pharmaceutical composition is weighed according to the weight ratio: 13g of Astragalus, 15g of Ziziphus jujuba seeds, 10g of Atractylodes macrocephala, 10g of Poria, 8g of Longan pulp, 8g of Angelica sinensis, 8g of Cuscuta australis, 8g of Plantago seed, 5g of dried ginger, 5g of ginseng, 3g of Styrax, 3g of Chuanxiong, 2g of Costus root, and 2g of Radix Glycyrrhizae.

3. The method for preparing a pharmaceutical composition according to claim 2, characterized in that: The specific steps are as follows: S1: Mix 13g of Astragalus, 15g of Ziziphus jujuba seeds, 10g of Atractylodes macrocephala, 10g of Poria, 8g of Longan pulp, 8g of Angelica sinensis, 8g of Cuscuta seeds, 8g of Plantago seeds, 5g of Dry ginger, 5g of Ginseng, 3g of Styrax, 3g of Chuanxiong, 2g of Aucklandia, and 2g of Radix Glycyrrhizae in a grinding chamber and crush them; S2: Soaking and refluxing the crushed pharmaceutical composition to prepare an oral dosage form.

4. The method for preparing a pharmaceutical composition according to claim 3, characterized in that: The astragalus 13g, spiny jujube seed 15g, white atractylodes 10g, poria 10g, longan pulp 8g, angelica 8g, dodder seed 8g, plantain seed 8g, dried ginger 5g, ginseng 5g, storax 3g, ligusticum 3g, costus root 2g, and licorice 2g are soaked in 95% ethanol solution, refluxed three times, each reflux time is 15h, the three refluxed medicinal solutions are combined, concentrated and dried to obtain an oral preparation.

5. The method for preparing a pharmaceutical composition according to claim 4, characterized in that: The oral preparation is taken once a day and combined with acupuncture treatment. The acupuncture treatment adopts alternating acupuncture of primary and secondary acupoints. The primary acupoints are infraorbital foramen and Sibai acupoint, and the secondary acupoints are Fengchi and Sanyinjiao.

6. The method for preparing a pharmaceutical composition according to claim 5, characterized in that: The alternating acupuncture adopts light twisting, lifting and inserting strengthening therapy.